Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$8,174 Mln
Revenue (TTM)
$8,103 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
6 %
P/E Ratio
14.2
P/B Ratio
0.8
Industry P/E
--
EV/EBITDA
9.1
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$--
EPS
$7.4
Face value
--
Shares outstanding
76,359,932
CFO
$4,582.19 Mln
EBITDA
$6,817.54 Mln
Net Profit
$3,242.57 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ICON - ADR
| -37.3 | 5.6 | -37.3 | -31.4 | -18.8 | -10.8 | 4.2 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
ICON - ADR
| -13.1 | 45.7 | -37.3 | 58.8 | 13.2 | 33.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development,... management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland. Address: South County Business Park, Dublin, Ireland, D18 X5R3 Read more
Founder & Independent Non-Executive Director
Dr. John Climax Ph.D.
Founder & Independent Non-Executive Director
Dr. John Climax Ph.D.
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ICON plc - ADR is $114.19 (NASDAQ) as of 02-Apr-2026 17:29 EDT. ICON plc - ADR has given a return of -18.84% in the last 3 years.
The P/E ratio of ICON plc - ADR is 14.16 times as on 31-Mar-2026.
The P/B ratio of ICON plc - ADR is 0.82 times as on 31-Mar-2026, a 54 discount to its peers’ median range of 1.78 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
21.79
|
1.81
|
|
2023
|
38.42
|
2.55
|
|
2022
|
31.70
|
1.88
|
|
2021
|
167.46
|
3.18
|
|
2020
|
31.70
|
5.62
|
The 52-week high and low of ICON plc - ADR are Rs 211.00 and Rs 66.57 as of 04-Apr-2026.
ICON plc - ADR has a market capitalisation of $ 8,174 Mln as on 31-Mar-2026. As per SEBI classification, it is a company.
Before investing in ICON plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$2.77
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.